| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 11, 2026 | UK AI drug safety startup Sable Bio raises €3.15 million; plans to grow its London team | Sable Bio, a London-based AI drug safety startup, today announced that it has raised €3.2 million in Seed funding to scale its platform.
The round was led by MMC Ventures, with participation from existing investors Episode 1 Ventures and Se... |
| Jan 26, 2026 | [Opinion] 2026: The Dawn of AI-Driven Drug Development | (Yicai) Jan. 23 -- The next big leap for artificial intelligence in healthcare is no longer in the lab, but in clinical trials -- where drug development succeeds or fails.
For years, the conversation around AI in healthcare has been dominat... |
| Dec 19, 2025 | The rise and impact of AI in Biotechnology and Healthcare | |
| Dec 17, 2025 | London Fuels UK’s Fintech Hiring Surge | Image: Unplash
The UK can thank London’s fintech sector, as it’s experiencing its strongest hiring surge since 2021.
New data from Morgan McKinley shows the capital is forecast to see a 37% year-on-year rise in vacancies for 2026.
London re... |
| Jul 1, 2025 | Beyond the hype: How GenAI is solving real business challenges across Africa | By Benedicta Etafo
In 2022, Generative AI (GenAI) exploded into public consciousness, capturing imaginations with chatbots that could write poems, design logos, and explain quantum physics in plain English. For months, it felt like a Silico... |
| Mar 28, 2025 | Schroders upgrades Revolut stake in former Woodford trust by 85 per cent | A Schroders trust formerly run by star stockpicker Neil Woodford has upgraded the value of its stake in Revolut by 85 per cent, implying the fintech firm is worth $48bn (£37.1bn).
The Schroders valuation would put Revolut, which has been mu... |
| Jan 15, 2025 | UK set for AI tech boost as millions of pounds injected after action plan | |
| Mar 11, 2024 | Artificial Intelligence in Healthcare Market Size, Share And Growth Analysis For 2024-2033 | Artificial Intelligence In Healthcare Global Market Report 2024 – Market Size, Trends, And Global Forecast 2023-2032
The Business Research Company's Artificial Intelligence In Healthcare Global Market Report 2024 – Market Size, Trends, And ... |
| Sep 20, 2023 | BenevolentAI Signs Strategic Collaboration with Merck | Collaboration utilises BenevolentAI’s end-to-end AI platform capabilities to deliver novel drug candidates, initially for three targets in oncology, neurology and immunology
BenevolentAI to identify and develop innovative compounds through ... |
| Aug 31, 2023 | BenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target | BenevolentAI, a leader in the development of advanced AI that accelerates biopharma discovery, announces that the first participants have been dosed in Phase I first-in-human studies of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8... |
| Jun 21, 2023 | Sanofi Goes All-In On AI | Chief Executive Officer of French pharmaceutical giant Sanofi, Paul Hudson, Paris, September 8, ... [+] 2021. (Photo by JOEL SAGET / AFP) (Photo by JOEL SAGET/AFP via Getty Images)AFP via Getty Images |
| Jun 6, 2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 6th June 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| Jun 5, 2023 | BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies | BenevolentAI , a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-3471... |
| May 25, 2023 | BenevolentAI Unveils Strategic Plan to Position the Company for a New Era in AI | BenevolentAI, a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development, announced a strategic review approved by its Board of Directors.
AiThority Interview Insights: AiT... |
| Apr 5, 2023 | BenevolentAI Announces Top-Line Phase IIa Results for Its Topical pan-Trk Inhibitor BEN-2293 (1%) in Mild-to-Moderate Atopic Dermatitis | BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI) announces top-line results from its Phase IIa, randomised, double-blind, placebo-controlled study of BEN-2293, a topical pan-Trk inhibitor. BEN-2293 is a selective inh... |
| Sep 12, 2022 | How WhiteLab Genomics is using AI to aid gene and cell therapy development | French biotech company WhiteLab Genomics has raised $10 million in funding for an AI platform designed to aid the discovery and development of genomic therapies.
Founded out of Paris in 2019, recent Y Combinator (YC) graduate WhiteLab Genom... |
| Apr 25, 2022 | London’s BenevolentAI lists on Euronext Amsterdam to boost drug discovery in Europe | London-headquartered clinical-stage AI-enabled drug discovery company, BenevolentAI has begun trading on Euronext Amsterdam. The listing follows the completion of its business combination with Amsterdam-listed Odyssey. Odyssey had bought Be... |
| Mar 2, 2022 | Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022 | “AI will continue to have a demonstrable impact on human health. Having spent the last three years ideating with my fellow charter members to establish AAIH, I’m honored to take the reins and thrilled I get to engage with an incredible team... |
| Feb 15, 2022 | Pasadena Biotech Terray Raises $60 Million to Speed Up Drug Discovery | After three years in stealth mode, a Pasadena biotech startup has emerged with $60 million and, it believes, a new way to create drugs.
Terray Therapeutics launched on Tuesday with $60 million in Series A funding led by Madrona Venture Grou... |
| Dec 13, 2021 | #TechCEO Joanna Shields: The Tech Veteran and Baroness Leading BenevolentAI | Isabella James, Tech Times 13 December 2021, 07:12 am
Joanna Shields has held and continues to hold many titles in life and career. She used to be the Minister for Internet Safety and Security of the United Kingdom and is the first one to h... |
| Dec 6, 2021 | Odyssey Acquistion S A : Acquisition S.A., - announces agreement to combine with BenevolentAI | NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SE... |
| Dec 6, 2021 | Odyssey Announces Agreement to Combine with BenevolentAI | BenevolentAI is a leading, clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting edge science to discover and develop novel and more effective medicines
Combination of BenevolentAI with Odyssey... |
| Dec 6, 2021 | Odyssey Announces Agreement to Combine with BenevolentAI | LONDON and AMSTERDAM, Dec. 6, 2021 /PRNewswire/ -- Odyssey Acquisition S.A. ("Odyssey"), a Euronext Amsterdam-listed special-purpose acquisition company, and BenevolentAI, a leading clinical-stage AI drug discovery company, today ... |
| Nov 29, 2021 | UK impact startups raise €2.36B to solve the world’s biggest challenge: Know more here | As technology becomes all important in solving global problems such as climate change, escalating health risks, and food insecurity, UK impact tech startups – companies founded to build solutions to the UN Sustainable Development Goals – ha... |
| Oct 14, 2021 | BenevolentAI Identifies Novel Target For Ulcerative Colitis And Advances Candidate To IND/CTA-Enabling Studies | – The Benevolent PlatformTM for AI-driven drug discovery identified and validated a novel biological target not previously linked to the disease – BenevolentAI researchers nominated preclinical candidate within two years of novel target val... |
| Sep 24, 2021 | ИИ помог создать комбинацию препаратов для лечения детей с редкой формой рака мозга | Специалисты Института исследований рака в Лондоне и Королевского фонда национальной системы здравоохранения имени Марседена разработали систему поддержки принятия врачебных решений для онкологов. Она обнаружила редкое сочетание препаратов д... |
| Jul 9, 2021 | BenevolentAI : announces the appointment of biopharma luminary Dr François Nader as Chairman | LONDON, July 9, 2021 /PRNewswire/ -- BenevolentAI announces the appointment of Dr François Nader as Chairman.
Dr Nader is an experienced biopharma executive currently serving as Chairman of Talaris, Acceleron Pharma, independent Board Direc... |
| Feb 17, 2021 | What does it take to scale a deeptech company? | Diffblue, a deeptech company that saves developers time by automating the writing of code, span out of Oxford University in 2016. It raised the largest AI Series A funding in Europe with Goldman Sachs a year later.
“The first thing you loo... |
| Jan 27, 2021 | BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target | BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
27-01-2021
BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney di... |
| Jul 14, 2020 | The nominees for the VentureBeat AI Innovation Awards at Transform 2020 | Watch all the Transform 2020 sessions on-demand right here.
At our AI-focused Transform 2020 event, taking place July 15-17 entirely online, VentureBeat will recognize and award emergent, compelling, and influential work through our second ... |
| Jul 14, 2020 | The nominees for the VentureBeat AI Innovation Awards at Transform 2020 | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
At our AI-focused Transform 2020 event, taking pl... |
| Jul 10, 2020 | Five Of The Leading British AI Companies Revealed | Amid the Covid-19 gloom, many cutting-edge technology companies have quietly been getting on with raising finance – with artificial intelligence emerging as a particular focus for investors. Last month, for example, London-based Temporall r... |
| London’s BenevolentAI lists on Euronext Amsterdam to boost drug discovery in Europe | London-headquartered clinical-stage AI-enabled drug discovery company, BenevolentAI has begun trading on Euronext Amsterdam. The listing follows the completion of its business combination with Amsterdam-listed Odyssey. Odyssey had bought Be... |
| Schrödinger: инвестиции в drug discovery и materials science. Есть ли перспективы после падения акций на 70%? | Для инвесторов в биотех и фармацевтические компании последний год выдался непростым. Популярный ETF SPDR S&P Biotech, он же XBI, состоящий в основном из биотехов малой и средней капитализации, потерял уже более 40% с пиковых значений в ... |
